TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21147163
Drug: Physostigmine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine infusion (cholinergic challenge)
Study: 20939783
Drug: Randomized controlled
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized controlled trials (RCTs) involving orthopedic implants
Study: 10688340
Drug: Low TENS
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low TENS treatment
Study: 1558292
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 ml of 100% alcohol/kg body weight)
Study: 6234558
Drug: Microgranules of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microgranules of dihydroergotamine (30 mg/24 hours)
Study: 6234558
Drug: Dihydroergotamine solution
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine solution (similar dose)
Study: 20818855
Drug: Four cycles
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of ABVD followed by 30 Gy of radiation therapy (group 1)
Study: 20818855
Drug: Four cycles
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of ABVD followed by 20 Gy of radiation therapy (group 2)
Study: 20818855
Drug: Two cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of ABVD followed by 20 Gy of radiation therapy (group 4)
Study: 16155169
Drug: Percutaneous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection without aspiration (group A)
Study: 16155169
Drug: Percutaneous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection with aspiration (group B)
Study: 14621286
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate solution (SP)
Study: 10971240
Drug: Lansoprazole 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 7.5 mg
Study: 23748485
Drug: Palonosetron 0.25
Normalized name: palonosetron 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.25 mg IV (PAD)
Study: 23748485
Drug: Ondansetron 24
Normalized name: ondansetron 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 24 mg orally (OAD)
Study: 12598499
Drug: Oral mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mixed micellar K(1) 2 mg (compared to healthy infants)
Study: 10080041
Drug: Nicodermal patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicodermal patch
Study: 31740426
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine (NAC) followed by oral ramipril for 12 weeks
Study: 29908297
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravenous zoledronic acid (ZOL) every 3 months
Study: 21950312
Drug: Spironolactone 25mg
Normalized name: SPIRONOLACTONE 25MG TAB
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 25mg daily for 4 weeks followed by randomization to treatment or placebo for 36 weeks
Study: 20684019
Drug: KIDNET (narrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: KIDNET (narrative exposure therapy)
Study: 18277346
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg daily for 5 days after abortion (Group A)
Study: 18277346
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg daily for 3 days after abortion (Group B)
Study: 18277346
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg daily one day before and 2 days after abortion (Group C)
Study: 11954884
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg orally three times a day
Study: 7670452
Drug: Carbohydrate drink
Normalized name: Ensure Pre-Surgery Clear Carbohydrate Drink (Strawberry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate drink containing 1 g.kg‐1 of carbohydrate four times daily
Study: 6770731
Drug: Methylprednisolone, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone, 0.5 mg/kg of body weight, intravenously every 6 h for 72 h
Study: 2015447
Drug: Day care
Normalized name: CVS Everyday Care Probiotic Vegetable Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day care treatment
Study: 15193686
Drug: Fasting glucose
Normalized name: FAST TAKE (GLUCOSE) METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting glucose levels (measured in mg/dl)
Study: 18568379
Drug: Standard educationally-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard educationally-based treatment group (n = 20)
Study: 19595251
Drug: Combined Therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Therapy Group (n = 22)
Study: 19595251
Drug: CBP Group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBP Group, Combined Therapy Group, Thymosin alpha(1) Group
Study: 22559218
Drug: NG‐monomethyl‐L‐arginine (L‐NMMA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐monomethyl‐L‐arginine (L‐NMMA)
Study: 11382368
Drug: Supervised group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised group (directly observed isoniazid therapy twice weekly)
Study: 11382368
Drug: Peer group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer group (daily self‐administered isoniazid with peer counseling and education)
Study: 9233181
Drug: Daily log
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily log
Study: 30977385
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg every 3 weeks with chemotherapy (capecitabine or gemcitabine/carboplatin)
Study: 30977385
Drug: Placebo every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every 3 weeks with chemotherapy (capecitabine or gemcitabine/carboplatin)
Study: 12816022
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care
Study: 11230282
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C repletion with 117 mg/d for 1 month after 1 month of depletion
Study: 9035281
Drug: Isotonic 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic 0.9% NaCl solutions (IS, n = 111)
Study: 3297375
Drug: Sublingual lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual lorazepam combined with high-dose metoclopramide (3 mg/kg) infused twice 3 h apart without i.v. dexamethasone
Study: 31680180
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) administered on Day 0-3
Study: 31680180
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) administered on Day 4-7
Study: 27571099
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran (4.5, 13.6 or 27.3 g) mixed in water
Study: 24014477
Drug: Analytic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analytic group therapy
Study: 21910945
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of broccoli sprouts and GRP powder
Study: 19286192
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract EGb 761 (240 mg/day)
Study: 11380294
Drug: EPO (NeoRecormon)
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO (NeoRecormon) and oral iron for 4 weeks prior to surgery
Study: 11380294
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron only for 4 weeks prior to surgery
Study: 9409274
Drug: High-fat meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meals (70 g of either rapeseed oil, olive oil, sunflower oil, palm oil, or butter)
Study: 8298714
Drug: Pentaglobin (PG)
Normalized name: PG
DrugBank: Pentaglobin (DB15865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaglobin (PG) 5 ml/kg/day
Study: 3681277
Drug: Diphenhydramine 50
Normalized name: diphenhydrAMINE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 50 mg (H-1 receptor antagonist)
Study: 31647775
Drug: Transcranial photobiomodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial photobiomodulation (t‐PBM) with near‐infrared light (NIR), self-administered daily for 20 minutes, 830 nm peak wavelength, average irradiance 30 mW/cm2, average fluence 36 J/cm2, total energy delivered per session 2.9 kJ.
Study: 23347793
Drug: sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham injection
Study: 9678815
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg o.m., clarithromycin 500 mg b.d. and secnidazole 2 g on alternate days for 1 week
Study: 31898517
Drug: Patient advice,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient advice, an insole, heavy-slow resistance training, and an ultrasound-guided corticosteroid injection
Study: 25201055
Drug: Stimulant medication
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medication prescription
Study: 8566261
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms transdermal E2 plus 5 mg medroxyprogesterone acetate (MPA) continuously
Study: 8566261
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen plus 2.5 mg MPA continuously
Study: 2107241
Drug: Pollinex-R hyposensitization
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pollinex-R hyposensitization injections
Study: 394282
Drug: Ibuprofen (Brufen)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (Brufen)
Study: 394282
Drug: Both Diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Diclofenac and Ibuprofen
Study: 28221862
Drug: Conventional high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional high-dose cytarabine (HDAC)
Study: 24440809
Drug: Acupuncture point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture point injection (group A)
Study: 22686081
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SFI) + routine therapy
Study: 17761829
Drug: Imatinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 600 mg/day
Study: 17761829
Drug: Imatinib <600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib <600 mg/day
Study: 17498108
Drug: Vardenafil 10
Normalized name: vardenafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 10 mg
Study: 10372934
Drug: Bismuth subcitrate
Normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subcitrate 120 mg four times daily + amoxycillin 500 mg three times daily + metronidazole 400 mg three times daily (group III, n = 22)
Study: 9389849
Drug: metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 10 mg i.v.
Study: 8839658
Drug: tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tropisetron 5 mg by slow i.v.i.
Study: 8839658
Drug: tropisetron by
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tropisetron by slow i.v.i., followed by 10 mg metoclopramide i.v.
Study: 26256137
Drug: Topical Matricaria
Normalized name: Matricaria chamomilla flowering top oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Matricaria chamomilla (Chamomile) oil, applied 3 times/day for 3 weeks
Study: 15505446
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at rates of 0.1, 0.3, 0.5, 0.7, or 0.9 microg . ml . min
Study: 27647873
Drug: Eluxadoline 1000
Normalized name: ELUXADOLINE
DrugBank: Eluxadoline (DB09272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eluxadoline 1000 mg
Study: 28167156
Drug: Eluxadoline 100
Normalized name: eluxadoline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eluxadoline 100 mg
Study: 29071928
Drug: CANT-3.0 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: CANT-3.0 g group
Study: 23265344
Drug: n‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFA (1 g/day)
Study: 21211295
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir 1000 mg 3 times per day for 8 weeks
Study: 21211295
Drug: 0.15% ganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% ganciclovir ophthalmic gel, 4 times per day, and 0.1% fluorometholone eye drops, 3 times per day (test group)
Study: 21211295
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same ophthalmic gel and eye drops without oral ganciclovir)
Study: 10803938
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g/8 h)
Study: 8628614
Drug: Nebulized adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized adrenaline (4 mg/4 mL)
Study: 1320305
Drug: Anticholest (apple-pectin-guar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholest (apple-pectin-guar soft-drink) at 1 cup (17 g) every second day
Study: 3535565
Drug: Meptazinol 3
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 3 mg kg‐1
Study: 16468292
Drug: Oral antibiotics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics, oral contraceptives, and topicals control (2 patients)
Study: 7903132
Drug: Diclofenac retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac retard 100 mg + Roxatidine 150 mg
Study: 7903132
Drug: Diclofenac retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac retard 100 mg + Placebo
Study: 19740126
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg/day
Study: 30008985
Drug: H1 antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 antihistamines (both desloratadine and levocetirizine)
Study: 24184313
Drug: 2.5mg once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg once-daily risedronate
Study: 24184313
Drug: 75mg once-monthly
Normalized name: vibegron
DrugBank: Vibegron (DB14895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75mg once-monthly risedronate
Study: 15918057
Drug: Perindopril (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (8 mg/day)
Study: 12453126
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of four ITI implants with Octa abutments and a U-shaped Dolder gold bar after 2 days.
Study: 12453126
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of four ITI implants with Octa abutments after 3-4 months.
Study: 12453126
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of implants with a U-shaped bar.
Study: 23160261
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (CYP)
Study: 19841835
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy for the upper limb
Study: 26869679
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug (ND)
Study: 9009296
Drug: CVD 908-htrA
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 908-htrA and CVD 906-htrA vaccine strains at doses of 5 x 10(8) to 5 x 10(9) CFU
Study: 9009296
Drug: CVD 908-htrA
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 908-htrA and CVD 906-htrA vaccine strains
Study: 9009296
Drug: CVD 908-htrA
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 908-htrA and CVD 906-htrA vaccine strains at higher doses
Study: 28834248
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA; 75 mg)
Study: 28834248
Drug: Ibuprofen (IBU;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (IBU; 1200 mg)
Study: 26518190
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg taken with a meal (Met protocol)
Study: 18250365
Drug: Dietary nitrate
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary nitrate load (beetroot juice 500 mL)
Study: 11826763
Drug: Urinary follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary follicle-stimulating hormone (FSH)
Study: 8113458
Drug: Isotretinoin 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 0.1% cream applied twice daily for 24 weeks
Study: 25183453
Drug: Beer (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beer (30 g alcohol/d, 660 mL)
Study: 25183453
Drug: Non‐alcoholic beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐alcoholic beer (990 mL)
Study: 25183453
Drug: Gin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gin (30 g alcohol/d, 100 mL)
Study: 9342580
Drug: Valsartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (160 mg) + Atenolol (100 mg)
Study: 2674029
Drug: Zopiclone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (7.5 mg/per os/day)
Study: 2674029
Drug: Nitrazepam (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam (5.0 mg/per os/day)
Study: 4731336
Drug: Amitriptyline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (10 to 60 mg, usually taken at night)
Study: 23220855
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (Group OP)
Study: 21496253
Drug: High-dose tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tranexamic acid (TA)
Study: 26291137
Drug: FF/VI 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 100/25 mcg
Study: 16850247
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel plus trastuzumab (4 mg/kg loading dose, then weekly 2 mg/kg)
Study: 16850247
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel alone (80 mg/m2)
Study: 16850247
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel plus trastuzumab
Study: 12161089
Drug: Baseline and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline and follow-up surveys on intervention dose
Study: 9612600
Drug: Intravenous 131I-polyclonal
Normalized name: iobenguane (131I)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous 131I-polyclonal antiferritin (added to either regimen)
Study: 7927192
Drug: Pyridostigmine (PD),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (PD), 120 mg po
Study: 7927192
Drug: Hydrocortisone succinate
Normalized name: Hydrocortisone succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone succinate infusion (100 mg bolus followed by 250 mg infusion)
Study: 2521027
Drug: Nicardipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (5 mg)
Study: 30705602
Drug: S-8117 (controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-8117 (controlled-release oxycodone)
Study: 18198636
Drug: Routine Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Western medicine treatment
Study: 7552649
Drug: Full-time, intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-time, intensive 3-week multidisciplinary program, including active physical and ergonomic training and psychological pain management, followed by 1 day weekly for the subsequent 3 weeks
Study: 7552649
Drug: Active physical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active physical training, twice a week for 6 weeks, for a total of 24h
Study: 7552649
Drug: Psychological pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological pain management combined with active physical training, twice a week for 6 weeks, also for a total of 24h
Study: 20634639
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for 6 and 12 months
Study: 20634639
Drug: Matched controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched controls (no GH treatment)
Study: 17685990
Drug: Healthcare site
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Healthcare site (alcohol treatment need)
Study: 15563363
Drug: Multidisciplinary service
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary service model delivering medication review including GP education, patient home visits, pharmacist medication reviews, primary healthcare team conferences, GP implementation of action plans, and follow-up surgery visits.
Study: 2979271
Drug: Kreon (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kreon (3.6 g/day)
Study: 354397
Drug: Timolol ophthalmic
Normalized name: timolol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol ophthalmic solution
Study: 3678263
Drug: Amiodarone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (200 mg day-1)